Introduction
============

Chronic heart failure (CHF) is a very common condition in the aged population, with a prevalence of up to 12%.[@b1-cia-8-1539] It is characterized by high mortality, which reaches 50% in the 5 years following diagnosis.[@b2-cia-8-1539] No less importantly, CHF affects daily functioning in elderly patients, ultimately impairing their health-related quality of life (HRQOL).[@b3-cia-8-1539] HRQOL is defined as the patient's subjective perception of the influence of disease on their everyday life.[@b4-cia-8-1539] In patients with CHF, HRQOL may be impaired by symptoms of the disease (dyspnea, fatigue), psychologic disorders (anxiety, depression), adverse effects of drugs, and costs of treatment.[@b4-cia-8-1539]--[@b8-cia-8-1539]

Previous studies have shown that HRQOL in CHF patients is predominantly influenced by New York Heart Association (NYHA) class, indicating that those with higher NYHA class have poorer HRQOL.[@b3-cia-8-1539]--[@b6-cia-8-1539],[@b9-cia-8-1539]--[@b12-cia-8-1539] Although left ventricular ejection fraction (LVEF) is an important predictor of survival in CHF patients, data from the literature suggest that HRQOL is equally impaired in patients with preserved and reduced LVEF.[@b5-cia-8-1539],[@b11-cia-8-1539],[@b13-cia-8-1539] In addition, earlier studies have identified advanced age, female sex, depression, and treatment with aldosterone antagonists as factors having a negative influence on HRQOL in CHF patients,[@b7-cia-8-1539]--[@b10-cia-8-1539],[@b14-cia-8-1539] while improvement of HRQOL was noted in subjects taking angiotensin-converting enzyme inhibitors and beta-blockers.[@b15-cia-8-1539]

Previous studies on HRQOL in elderly CHF patients have included mostly outpatients,[@b3-cia-8-1539],[@b9-cia-8-1539],[@b10-cia-8-1539],[@b16-cia-8-1539]--[@b21-cia-8-1539] so little is known about determinants of HRQOL in the hospitalized elderly population,[@b22-cia-8-1539]--[@b26-cia-8-1539] especially in Serbia, where only one paper (that covered a younger population) has been published so far.[@b27-cia-8-1539] In addition, studies performed in hospitalized elderly patients with CHF have paid little or no attention to the effects that multiple medication usage, depression, and cognitive impairment, which are very common among elderly patients, have on HRQOL. Accordingly, in this study we tried to identify demographic and clinical variables, including depression, cognitive status, and medication usage, that influence HRQOL in elderly patients hospitalized with CHF in Serbia.

Patients and methods
====================

Study population and design
---------------------------

The study population consisted of 136 consecutive elderly patients hospitalized for CHF at the geriatric department of Zvezdara University Hospital in Belgrade, Serbia, between February 2009 and October 2011. Inclusion criteria were age ≥65 years and an established diagnosis of CHF. Exclusion criteria were cancer in the terminal phase, end-stage renal failure, previous stroke with immobility, and severe dementia. Diagnosis of CHF was made according to the guidelines for the diagnosis and treatment of CHF from the European Society of Cardiology.[@b28-cia-8-1539]

Sociodemographic and clinical characteristics
---------------------------------------------

Patients were interviewed in order to obtain sociodemographic data, ie, age, sex, marital status, educational level, and household information, such as number of household members and income. Clinical data collected from the medical history included duration of CHF, length of hospital stay, history of previous myocardial infarction, angina, hypertension, and diabetes, as well as current medication. NYHA class was determined for each patient according to their symptoms. LVEF was assessed by echocardiography using the modified Simpson's rule.

Health-related quality of life
------------------------------

HRQOL was assessed using the Serbian version of the Minnesota Living with Heart Failure Questionnaire (MLHFQ), which is one of the most commonly used disease-specific instruments for measuring HRQOL in heart failure, with proven reliability and validity.[@b29-cia-8-1539],[@b30-cia-8-1539] The questionnaire consists of 21 items asking how much the disease and its treatment have affected the patient's life in the previous month. Available responses for each question range from 0 (no effect) to 5 (very much). The total score is calculated by adding ratings from all 21 items and can range from 0 to 105 points, with higher scores indicating poorer HRQOL. In addition to total score, MLHFQ measures the physical (eight items; range 0--40) and emotional (five items; range 0--25) dimensions of HRQOL.

Depressive symptoms and cognitive status
----------------------------------------

The presence of depressive symptoms was assessed by the five-item Geriatric Depression Scale.[@b31-cia-8-1539] Total score can range from 0 to 5, with a result ≥2 points indicating possible depression. The presence of cognitive impairment was tested by the Mini-Mental State Examination, and subjects with scores \<25 were considered to be cognitively impaired.[@b32-cia-8-1539]

Statistical analysis
--------------------

Continuous variables are presented as the mean ± standard deviation, while categoric data are expressed as the numbers and percentage. Differences between independent groups were calculated using the Student's *t*-test for normally distributed variables and the Mann-Whitney *U* test for non-normally distributed variables. Correlations were calculated using Pearson's correlation coefficient for linear relationships, and with Spearman's rank correlation coefficient for nonlinear relationships between two variables. Factors predictive of HRQOL were identified using multiple linear regression analysis. The regression model included variables related to the MLHFQ score with *P*\<0.10 calculated in univariate analysis. All *P*-values \<0.05 were considered to be statistically significant.

Ethical considerations
----------------------

All participants gave their written informed consent. The study was approved by the local ethics committee and performed in accordance with the Declaration of Helsinki.

Results
=======

Baseline patient characteristics
--------------------------------

The baseline patient characteristics are presented in [Table 1](#t1-cia-8-1539){ref-type="table"}. The mean patient age was 77.8 years, and males comprised the majority. More than two thirds of subjects were in NYHA classes III and IV. The mean LVEF was 40.9%. Depressive symptoms and cognitive impairment were present in more than half of our patients. The mean total MLHFQ score was 50.4.

Factors associated with HRQOL
-----------------------------

We have presented demographic and clinical characteristics, as well as medications and their associations with total, physical, and emotional MLHFQ score. Demographic factors related to HRQOL are shown in [Table 2](#t2-cia-8-1539){ref-type="table"}. We found no correlation between age and HRQOL, and no significant difference between male and female patients regarding HRQOL. The educational level of patients correlated positively with the physical dimension of HRQOL (*P*=0.038), but not with total or emotional MLHFQ score. Household income correlated negatively with total (*P*=0.013) and physical score (*P*=0.012) on the MLHFQ, but not with the emotional dimension (*P*=0.576), indicating that patients with higher income had better overall HRQOL and its physical dimension. With regard to number of household members, we found an inverse correlation with the emotional dimension of HRQOL (*P*=0.035).

Clinical factors related to HRQOL are shown in [Table 3](#t3-cia-8-1539){ref-type="table"}. Duration of CHF correlated negatively with HRQOL and its physical dimension (*P*=0.010 and *P*=0.011, respectively), but not with its emotional dimension (*P*=0.085). We found no difference in HRQOL between patients with and without a history of previous myocardial infarction, angina, hypertension, and diabetes. There was no correlation between number of comorbidities and MLHFQ scores.

Patients with higher NYHA class (III or IV) had worse overall HRQOL, including its physical and emotional dimensions (*P*\<0.001, *P*\<0.001, and *P*=0.023, respectively). We noticed no difference in HRQOL between subjects with preserved and reduced LVEF.

Subjects with depressive symptoms had poorer overall HRQOL, including its physical and emotional domains, than their nondepressive counterparts (*P*\<0.001, *P*\<0.001, and *P*\<0.001, respectively). Patients with cognitive impairment had worse overall HRQOL and its emotional dimension than those with preserved cognitive function (*P*=0.030 and *P*=0.022, respectively).

Length of hospital stay correlated inversely with overall HRQOL and its emotional dimension (*P*=0.021 and *P*=0.020, respectively).

Current medications and their association with HRQOL are presented in [Table 4](#t4-cia-8-1539){ref-type="table"}. Patients receiving aldosterone antagonists and digoxin had worse HRQOL (*P*=0.046 and *P*=0.049, respectively). Further, patients on aldosterone antagonists had a worse physical dimension of HRQOL (*P*=0.048). We did not perform a statistical analysis on use of angiotensin II receptor blockers and HRQOL due to the small number of patients involved (2.2%). We found an inverse correlation between the number of drugs that patients were taking and HRQOL (*P*=0.047).

Independent predictors of HRQOL are shown in [Table 5](#t5-cia-8-1539){ref-type="table"}. Multiple linear regression analysis showed that the presence of depressive symptoms (*Sβ*=0.407; *P*\<0.001), higher NYHA class (*Sβ*=0.229; *P*=0.021), lower income (*Sβ*=−0.206; *P*=0.029), and longer duration of heart failure (*Sβ*=0.179; *P*=0.049) were independent predictors of poorer HRQOL.

Discussion
==========

To our knowledge, this study is the first to assess determinants of HRQOL in elderly patients with heart failure in Serbia, and one of only few that have examined HRQOL in the hospital setting.[@b12-cia-8-1539],[@b22-cia-8-1539]--[@b26-cia-8-1539] We used MLHFQ to evaluate HRQOL in our subjects. The mean MLHFQ score in our patients was higher than values reported by the majority of other studies, indicating poorer HRQOL in our study population.[@b5-cia-8-1539],[@b10-cia-8-1539],[@b11-cia-8-1539],[@b24-cia-8-1539] Reasons for this finding lie in the fact that more than two thirds of our subjects were in NYHA class III or IV, as well as in the negative impact of hospitalization on HRQOL.[@b33-cia-8-1539]

Our patients were older than the subjects included in most previous studies.[@b3-cia-8-1539],[@b5-cia-8-1539],[@b6-cia-8-1539],[@b11-cia-8-1539]--[@b14-cia-8-1539] We found no correlation between age and HRQOL, which is in accordance with the findings of Kato et al[@b5-cia-8-1539] and Westlake et al.[@b6-cia-8-1539] Other authors have found either a positive[@b3-cia-8-1539],[@b13-cia-8-1539] or a negative association between age and HRQOL.[@b10-cia-8-1539],[@b11-cia-8-1539] We did not observe sex differences in MLFHQ score, which is consistent with the findings of Heo et al,[@b3-cia-8-1539] while other studies have reported worse HRQOL in women.[@b5-cia-8-1539],[@b9-cia-8-1539]--[@b11-cia-8-1539],[@b13-cia-8-1539] Marital status had no influence on HRQOL in our subjects, which is similar to the findings reported by Kato et al[@b5-cia-8-1539] and Westlake and al,[@b6-cia-8-1539] and different from the results published by Luttik et al, who found better HRQOL in married subjects.[@b34-cia-8-1539] The education level of our patients correlated negatively only with physical MLHFQ score, but not with total or emotional score, suggesting that more highly educated subjects have a better physical HRQOL dimension. This is in accordance with the findings of Barbareschi et al, who reported better physical HRQOL in more highly educated patients.[@b35-cia-8-1539] We found no association between number of household members and total or physical MLHFQ score, which is similar to the results of Kato et al[@b5-cia-8-1539] but different from the findings of Luttik et al, who reported poorer HRQOL in patients living alone.[@b34-cia-8-1539] Our study shows an inverse correlation between number of family members and the emotional dimension of HRQOL, which is in contrast with the findings of Franzen et al, who reported a similar emotional dimension of HRQOL in patients living alone and those living with family.[@b10-cia-8-1539] Our findings indicate that a higher household income is associated with better overall HRQOL and its physical but not emotional dimension, so correspond partially with the results of Clark et al, who observed better physical and emotional domains of HRQOL in subjects with higher income.[@b36-cia-8-1539]

The average length of CHF prior to study enrolment was a little more than 5 years, which is similar to the findings of Allen et al[@b12-cia-8-1539] and longer than indicated by other authors.[@b5-cia-8-1539] We found an inverse correlation between duration of CHF and HRQOL and its physical domain, which is consistent with the results published by Allen et al[@b12-cia-8-1539] and differs from those of Kato et al, who found no significant relationship between length of CHF and HRQOL.[@b5-cia-8-1539]

In our study, a history of prior myocardial infarction, angina, hypertension, and diabetes was not associated with worse HRQOL. Previous studies have demonstrated that CHF of ischemic etiology is not associated with worse HRQOL,[@b5-cia-8-1539],[@b11-cia-8-1539] a finding consistent with ours, while Lewis et al found poorer HRQOL in CHF patients with angina.[@b13-cia-8-1539] Data from the literature do not suggest a relationship between hypertension and HRQOL in CHF, which is in accordance with our results.[@b10-cia-8-1539],[@b11-cia-8-1539] Franzen et al[@b10-cia-8-1539] found poorer HRQOL in patients with diabetes and CHF, while Kato et al[@b5-cia-8-1539] did not find any such association, the latter finding being similar to our results. Our study did not find any correlation between number of comorbidities and MLHFQ scores, which is different from the results of Gott et al, who reported poorer HRQOL in subjects with two or more coexisting diseases.[@b9-cia-8-1539]

This study shows that patients with higher NYHA class had worse HRQOL, including its physical and emotional domains, which is consistent with the results of previous studies.[@b5-cia-8-1539],[@b6-cia-8-1539],[@b9-cia-8-1539],[@b10-cia-8-1539],[@b12-cia-8-1539],[@b13-cia-8-1539] This finding is not surprising, given that the NYHA classification is based on symptoms of heart failure and the physical limitations of the disease as experienced by patients, and thereby reflects their HRQOL. We observed similar HRQOL in patients with preserved and reduced LVEF, which is in accordance with results published by others.[@b5-cia-8-1539],[@b11-cia-8-1539]--[@b13-cia-8-1539]

Depressive symptoms were present in more than one half of our patients. Previous studies have reported diverse prevalences of depression in patients hospitalized with heart failure (35%--70%) because of the different patient selection criteria and diagnostic tools used.[@b7-cia-8-1539] Our patients with depressive symptoms had worse HRQOL than nondepressive subjects, which is consistent with findings published by others.[@b5-cia-8-1539],[@b9-cia-8-1539],[@b14-cia-8-1539] Data from the literature suggest that depression is associated with a greater number and over-reporting of symptoms in CHF patients, which is a possible mechanism for poor HRQOL in such patients.[@b37-cia-8-1539] There is evidence that treatment of depression could improve HRQOL in CHF patients.[@b37-cia-8-1539]

More than half of our subjects had signs of cognitive impairment, which is similar to the finding reported by Heckman et al.[@b38-cia-8-1539] Our study indicates that cognitive impairment is related to poorer HRQOL, while Pressler et al did not find significant relationship between these variables.[@b39-cia-8-1539] Possible reasons for reduced HRQOL in patients with cognitive impairment might be poor adherence with medical therapy, frequent coexistence of depression, and different interpretation of symptoms in such a population.[@b38-cia-8-1539]--[@b40-cia-8-1539] We suggest screening for cognitive impairment in elderly patients with CHF, because data in the literature indicate that optimizing therapy for heart failure could possibly improve cognitive function.[@b38-cia-8-1539]

Our study shows that a longer length of hospital stay is associated with worse overall HRQOL and its emotional domain. Although the impact of hospitalization on HRQOL in the elderly is known,[@b33-cia-8-1539] previous studies have not assessed the influence of length of hospital stay on HRQOL in CHF patients. The possible influence of longer length of hospital stay on HRQOL could in fact be that prolonged hospitalization may lead to functional decline, worsening of cognitive impairment, and increased risk of iatrogenic injury.[@b33-cia-8-1539]

Regarding medication, we found that patients receiving aldosterone antagonists and digoxin had worse HRQOL. Our results are consistent with those reported by Berry et al,[@b8-cia-8-1539] who found worse HRQOL in CHF patients taking aldosterone antagonists, but different from those of other authors who found no association between use of digoxin and HRQOL.[@b5-cia-8-1539],[@b41-cia-8-1539]

Previous studies have shown a beneficial effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on HRQOL and a trend towards better HRQOL in patients receiving beta-blockers, which was not confirmed in our study.[@b15-cia-8-1539],[@b42-cia-8-1539],[@b43-cia-8-1539] We found an inverse correlation between the number of drugs that patients were taking and HRQOL. To the best of our knowledge, there are no previous papers published regarding this issue in CHF. However, polypharmacy in the elderly, and in patients with CHF, leads to unpredictable drug interactions and more frequent adverse effects, which might affect HRQOL.[@b44-cia-8-1539],[@b45-cia-8-1539] Bearing that in mind, we propose that clinicians should carefully review medication in patients with CHF and avoid potentially unnecessary therapy.

The results of multiple linear regression analysis in our study showed that the presence of depressive symptoms, higher NYHA class, lower income, and longer duration of heart failure were independent predictors of poor HRQOL, with depression being identified as probably the most influential factor affecting HRQOL in elderly patients with CHF. Considering the results obtained from this study and the previously published data, which point to depression as a common condition with a negative impact on HRQOL in patients with CHF, we propose that measuring HRQOL and screening for symptoms of depression in the elderly with CHF should be routine in everyday clinical practice in order to detect such patients and target them for appropriate intervention.

While previous studies have shown that cardiac resynchronization therapy, along with certain disease management and educational programs, are the only interventions that improve HRQOL in patients with heart failure,[@b46-cia-8-1539] results from studies performed in the elderly do not give us strong evidence of possible benefits from such interventions on HRQOL.[@b17-cia-8-1539] Therefore, more research is needed in the future. Considering that elderly patients with CHF often have a complex profile characterized by depression, cognitive impairment, multiple comorbidities, and polypharmacy, we suggest that the design of future interventional studies on HRQOL in this population include comprehensive geriatric assessment and follow-up, which might improve HRQOL in this vulnerable population.

Study limitations
-----------------

This study has several limitations. First, it is a single-center study performed in hospitalized elderly patients in one country, so the findings may not be generalizable. Second, we used only one disease-specific instrument to measure HRQOL (ie, the MLHFQ). Complementary use of other instruments, such as a generic HRQOL questionnaire (the Medical Outcomes Study Short-Form 36) or the disease-specific Kansas City Cardiomyopathy Questionnaire, would probably give us more insight into the HRQOL of our patients.[@b47-cia-8-1539],[@b48-cia-8-1539] Further, although the MLHFQ is one of the most recommended and commonly used questionnaires for measuring HRQOL in heart failure,[@b49-cia-8-1539] it has been used in only a small number of studies in hospitalized patients in the past and its reliability and validity is not as tested in this population as it is in outpatients.[@b23-cia-8-1539],[@b24-cia-8-1539],[@b50-cia-8-1539] With regard to questionnaires canvassing depression, we used only the five-item Geriatric Depression Scale and not other well established and widely used instruments, such as the Beck Depression Inventory or the Medical Outcome Study-Depression questionnaire.[@b51-cia-8-1539] Third, we did not compare the HRQOL of our subjects with that in younger heart failure patients or in the elderly without CHF. Finally, we did not perform subgroup analysis by type of heart failure (eg, diastolic versus systolic), although diastolic dysfunction is a common finding in elderly patients with CHF.[@b11-cia-8-1539] Instead, we compared subjects with preserved (≥40%) and reduced (\<40%) LVEF.

Conclusion
==========

Our study indicates that the presence of depressive symptoms, higher NYHA functional class, lower income, and longer duration of CHF are independent predictors of poor HRQOL in elderly patients hospitalized with CHF in Serbia. Further, we have highlighted the association between multiple medication usage and poor HRQOL, as well as the negative impact of cognitive impairment on HRQOL. Therefore, certain measures should be implemented to identify such patients, especially those with depressive symptoms, and appropriate interventions should be taken in order to improve their HRQOL.
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###### 

Baseline patient characteristics (n=136)

  Characteristic                           Value
  ---------------------------------------- -------------
  Age (years)                              77.8±5.9
  Male sex                                 72 (52.9)
  Marital status                           
   Married                                 47 (34.6)
   Single, divorced, widowed               89 (65.4)
  Education                                
   \>12 years                              27 (19.9)
   ≤12 years                               109 (80.1)
  Number of household members              2.4±1.4
  Household income (monthly, US dollars)   447.2±297.7
  Duration of CHF (months)                 61.9±71.1
  Previous                                 
   Myocardial infarction                   44 (32.4)
   Angina                                  80 (58.8)
  Hypertension                             101 (74.3)
  Diabetes mellitus                        42 (30.9)
  Three or more comorbidities              90 (66.2)
  Current medications                      
   Diuretics                               128 (94.1)
   Aldosterone antagonists                 67 (49.3)
   ACEIs                                   104 (76.5)
   ARBs                                    3 (2.2)
   Beta-blockers                           69 (50.7)
   Digoxin                                 41 (30.1)
   Anticoagulants                          51 (37.5)
  Number of drugs                          6.9±2.3
  NYHA class                               
   I                                       2 (1.5)
   II                                      36 (26.5)
   III                                     63 (46.3)
   IV                                      35 (25.7)
  LVEF (%)                                 40.9±11.0
  Depressive symptoms                      76 (55.9)
  Cognitive impairment                     71 (52.2)
  Length of hospital stay (days)           18.0±9.5
  MLHFQ score                              
   Total                                   50.4±19.3
   Physical                                25.3±9.4
   Emotional                               10.6±6.5

**Notes:** Data are presented as the mean ± standard deviation or number (%).

**Abbreviations:** CHF, chronic heart failure; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure questionnaire.

###### 

Demographic factors associated with health-related quality of life[a](#tfn3-cia-8-1539){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------
                                Total\        *P*-value   Physical\     *P*-value   Emotional\    *P*-value
                                MLHFQ score               MLHFQ score               MLHFQ score   
  ----------------------------- ------------- ----------- ------------- ----------- ------------- -----------
  Age                           −0.070        0.420       −0.043        0.620       0.024         0.777

  Gender                                                                                          

   Male                         48.6±19.7     0.227       24.0±9.8      0.075       10.1±6.0      0.264

   Female                       52.3±18.7                 26.9±8.8                  11.3±7.0      

  Marital status                                                                                  

   Married                      50.9±20.4     0.810       25.1±9.6      0.810       10.4±6.4      0.824

   Unmarried                    50.1±18.8                 25.5±9.4                  10.8±6.6      

  Education                     −0.135        0.118       −0.179        0.038       −0.142        0.102

  Number of household members   0.121         0.161       0.081         0.347       0.181         0.035

  Household income              −0.252        0.013       −0.254        0.012       −0.057        0.576
  -----------------------------------------------------------------------------------------------------------

**Notes:**

Univariate analysis. HRQOL was assessed using the MLHFQ; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation, Pearson's product-moment correlation coefficient, or Spearman's rank correlation coefficient.

**Abbreviations:** MLHFQ, Minnesota Living with Heart Failure questionnaire; HRQOL, health-related quality of life.

###### 

Clinical factors associated with health-related quality of life[a](#tfn5-cia-8-1539){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------
                            Total\        *P*-value   Physical\     *P*-value   Emotional\    *P*-value
                            MLHFQ score               MLHFQ score               MLHFQ score   
  ------------------------- ------------- ----------- ------------- ----------- ------------- -----------
  Duration of CHF           0.224         0.010       0.223         0.011       0.151         0.085

  Previous MI                                                                                 

   Yes                      52.0±19.0     0.373       25.5±10.3     0.684       11.2±6.2      0.418

   No                       49.6±19.4                 25.3±9.0                  10.4±6.6      

  Previous AP                                                                                 

   Yes                      51.6±19.0     0.325       25.8±9.9      0.344       10.8±6.6      0.796

   No                       48.6±19.6                 24.7±8.7                  10.5±6.4      

  Hypertension                                                                                

   Yes                      49.1±19.9     0.130       24.8±9.4      0.255       10.1±6.5      0.084

   No                       54.0±17.1                 26.9±9.5                  12.2±6.4      

  Diabetes mellitus                                                                           

   Yes                      49.8±17.9     0.904       24.0±8.9      0.180       11.3±6.7      0.365

   No                       50.6±19.9                 25.9±9.6                  10.3±6.4      

  Number of comorbidities   −0.053        0.538       −0.045        0.604       −0.039        0.649

  NYHA class                                                                                  

   I or II                  39.3±18.2     \<0.001     19.3±9.8      \<0.001     8.5±5.5       0.023

   III or IV                54.7±18.0                 27.7±8.2                  11.5±6.6      

  LVEF (%)                                                                                    

   ≥40                      49.3±18.7     0.661       25.1±9.1      0.699       10.7±6.4      0.568

   \<40                     51.5±19.9                 25.5±9.9                  10.4±6.6      

  Depressive symptoms                                                                         

   Yes                      57.9±17.6     \<0.001     28.5±8.9      \<0.001     13.1±6.4      \<0.001

   No                       40.9±17.1                 21.4±8.6                  7.5±5.0       

  Cognitive impairment                                                                        

   Yes                      53.8±20.7     0.030       26.6±9.8      0.062       12.1±7.2      0.022

   No                       46.7±17.0                 24.0±8.9                  9.1±5.2       

  Length of hospital stay   0.198         0.021       0.162         0.060       0.199         0.020
  -------------------------------------------------------------------------------------------------------

**Notes:**

Univariate analysis. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation, Pearson's product-moment correlation coefficient, or Spearman's rank correlation coefficient.

**Abbreviations:** MLHFQ, Minnesota Living with Heart Failure questionnaire; CHF, chronic heart failure; MI, myocardial infarction; AP, angina pectoris; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HRQOL, health-related quality of life.

###### 

Current medications associated with health-related quality of life[a](#tfn7-cia-8-1539){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------
                            Total\        *P*-value   Physical\     *P*-value   Emotional\    *P*-value
                            MLHFQ score               MLHFQ score               MLHFQ score   
  ------------------------- ------------- ----------- ------------- ----------- ------------- -----------
  Diuretics                                                                                   

   Yes                      51.1±19.4     0.060       25.6±9.4      0.109       10.8±6.6      0.496

   No                       38.4±13.9                 20.6±8.9                  8.9±4.1       

  Aldosterone antagonists                                                                     

   Yes                      53.7±20.2     0.046       26.9±9.3      0.048       11.4±7.0      0.231

   No                       47.2±17.9                 23.8±9.3                  9.9±6.0       

  ACEIs                                                                                       

   Yes                      50.8±20.2     0.731       25.0±9.5      0.443       11.1±6.7      0.230

   No                       49.0±16.2                 26.4±9.3                  9.2±5.6       

  Beta-blockers                                                                               

   Yes                      49.6±21.4     0.555       24.4±10.0     0.272       10.9±7.0      0.709

   No                       51.2±17.0                 26.3±8.7                  10.4±5.9      

  Digoxin                                                                                     

   Yes                      54.5±17.8     0.049       27.2±9.0      0.128       12.1±6.8      0.115

   No                       48.6±19.7                 24.6±9.5                  10.0±6.3      

  Anticoagulants                                                                              

   Yes                      49.6±19.0     0.681       24.3±8.8      0.219       10.5±6.6      0.751

   No                       50.8±19.5                 26.0±9.8                  10.7±6.4      

  Number of drugs           0.170         0.047       0.146         0.090       0.119         0.168
  -------------------------------------------------------------------------------------------------------

**Notes:**

Univariate analysis. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire; higher scores represent more impaired HRQOL. Data are presented as the mean ± standard deviation or Spearman's rank correlation coefficient.

**Abbreviations:** MLHFQ, Minnesota Living with Heart Failure questionnaire; ACEIs, angiotensin-converting enzyme inhibitors; HRQOL, health-related quality of life.

###### 

Independent predictors of health-related quality of life[a](#tfn9-cia-8-1539){ref-type="table-fn"}

                            *Sβ*     *P*-value
  ------------------------- -------- -----------
  Depressive symptoms       0.407    \<0.001
  NYHA class                0.229    0.021
  Duration of CHF           0.179    0.049
  Digoxin                   0.139    0.125
  Income                    −0.206   0.029
  Length of hospital stay   0.105    0.240
  Diuretics                 −0.039   0.682
  Cognitive impairment      0.005    0.959
  Aldosterone antagonists   −0.023   0.811
  Number of drugs           0.027    0.784

**Notes:**

Multiple linear regression analysis. *R*^2^=0.402; *R*^2^ (adjusted) =0.330. HRQOL was assessed using the Minnesota Living with Heart Failure questionnaire.

**Abbreviations:** HRQOL, health-related quality of life; NYHA, New York Heart Association; *Sβ*, standard partial regression coefficient; CHF, chronic heart failure; *R*^2^, coefficient of determination.
